Healthwise

Simian B Virus Infection


National Organization for Rare Disorders, Inc.

Synonyms

  • H Simiae Encephalomyelitis
  • Herpesvirus Simiae, B Virus
  • Monkey B Virus

Disorder Subdivisions

  • None

Related Disorders List

Information on the following diseases can be found in the Related Disorders section of this report:

  • Acute Disseminated Encephalomyelitis

General Discussion

Simian B Virus Infection is caused by a type of herpesvirus. It is an infectious disorder contracted chiefly by laboratory workers exposed to infected monkeys and/or simian tissue cultures. It is characterized by a viral invasion of the brain (Encephalitis) and the membranes (meninges) surrounding the brain. Occasionally, the infection affects the spinal cord structures as well (Encephalomyelitis). Neurological damage may result from this infection. Without treatment, some cases of Simian B Virus may be life- threatening.

Symptoms

Simian B Virus Infection is characterized by fever, headache, vomiting, discomfort (malaise), and a stiff neck and back. These symptoms may be associated with neuromuscular dysfunction, respiratory difficulties, vision problems, cranial nerve abnormalities, alteration of consciousness, personality changes, seizures and/or partial paralysis (paresis). Some patients may go into a coma.

Causes

Simian B Virus Infection is caused by herpesvirus simiae (also known as B virus), a type of herpesvirus that is highly prevalent (i.e., enzootic) among macaque monkeys, i.e., certain Asiatic monkeys belonging to the "Macaca" genus. According to some reports, up to 80 or 90 percent of adult macaques may be infected with the virus.

In humans, Simian B Virus Infection may result from exposure to contaminated saliva from infected monkeys (e.g., from bites or scratches) or to simian tissue cultures of the virus, usually in laboratory settings. In addition, there has been at least one instance in which person-to-person transmission occurred.

Affected Populations

According to reports in the medical literature, symptoms associated with Simian B Virus Infection typically occur within approximately two to five weeks after initial exposure.

Simian B Virus Infection usually occurs in an occupational setting in which employees have been bitten or scratched by infected monkeys or exposed to virus-infected simian tissue cultures. The disease was originally reported in a monkey handler in 1932. Through 1973, approximately 17 additional cases were reported in the medical literature. In addition, in 1987, four more individuals were affected by the disease, including the first documented case in which human-to-human disease transmission occurred. Fewer than a total of 40 cases of Simian B Virus Infection have been reported in humans to date. Researchers suggest, however, that the true frequency of Simian B Virus Infection may be difficult to assess, since it is possible that exposure to the virus may result in mild or no apparent symptoms (asymptomatic infection) in some cases.

Since 1975, United States public health regulations have prohibited the importation of primates as pets. However, according to researchers at the Centers for Disease Control and Prevention (CDC), there have been a number of incidents in nonoccupational settings in which individuals were exposed to the saliva of pet macaques (e.g., due to bites or scratches). According to one published CDC report, investigators examined seven nonoccupational exposures involving 24 individuals and eight monkeys. One exposed family had flu-like symptoms and another individual developed symptoms at the wound site suggesting infection. The researchers stress that infection must be assumed as a potential risk of macaque bite or scratch wounds, making macaques unacceptable as pets.

Related Disorders

Symptoms of the following disorders can be similar to those of Simian B Virus. Comparisons may be useful for a differential diagnosis:

Acute Disseminated Encephalomyelitis is an infection of the nervous system characterized by headache, irritability, vomiting, drowsiness, light- sensitivity, difficulty in swallowing, lockjaw, incontinence, and diminished or exaggerated skin sensations. This disorder can be caused by viral infections acquired from sources other than Simian B Virus infected monkeys. It may be an allergic or toxic response of the nervous system to invading organisms such as bacteria or viruses. Neurological damage and intellectual impairment can follow an attack of this condition. (For more information on this disorder, choose "Encephalomyelitis" as your search term in the Rare Disease Database.)

Standard Therapies

The Centers for Disease Control and Prevention (CDC) has published a series of guidelines for the prevention of Simian B Virus Infection among monkey handlers. Such guidelines include receiving training in appropriate methods of restraint and the use of proper protective clothing and equipment when handling potentially infected monkeys. The CDC and the National Institutes of Health (NIH) have also published guidelines concerning appropriate measures for working with the B virus in a laboratory setting. For further information, please contact the CDC and/or the NIH (listed in the "References" section of this report below).

According to reports in the literature, in some affected individuals, the antiviral drug acyclovir may be effective in treating Simian B Virus Infection. In some cases, therapy may include intravenous infusion of ganciclovir, an antiviral medication structurally related to acyclovir.

Other treatment for Simian B Virus Infection is symptomatic and supportive.

References

CECIL TEXTBOOK OF MEDICINE, 19th Ed.: James B. Wyngaarden et al., Eds.; W.B Saunders Company, 1992. Pp. 1796-97.

HARRISON’S PRINCIPLES OF INTERNAL MEDICINE, 14th Ed.: Anthony S. Fauci et al., Eds.: McGraw-Hill Companies, Inc., 1998. P. 836.

SUCCESSFUL TREATMENT OF EXPERIMENTAL B VIRUS (HERPESVIRUS SIMIAE) INFECTION WITH ACYCLOVIR. E.A. Boulter et al.; Br Med J (March 8 1980; 280(6215)). Pp. 681-83.

THE SPECTRUM OF ANTIVIRAL ACTIVITIES OF ACYCLOVIR IN VITRO AND IN VIVO. P. Collins; J Antimicrob Chemother (Sept 1983; 12 Suppl B). Pp. 19-27.

B VIRUS, HERPESVIRUS SIMIAE: HISTORICAL PERSPECTIVE. A.E. Palmer; J Med Primatol (1987; 16(2)). Pp. 99-130.

GUIDELINES FOR PREVENTION OF HERPESVIRUS SIMIAE (B VIRUS) INFECTION IN MONKEY HANDLERS. MMWR Morb Mortal Wkly Rep (Oct 23 1987; 36(41)). Pp. 680-82, 687-89.

DIAGNOSIS AND MANAGEMENT OF HUMAN B VIRUS (HERPESVIRUS SIMIAE) INFECTIONS IN MICHIGAN. D.S. Davenport et al.; Clin Infect Dis (Jul 1994; 19(1)). Pp. 33-41.

THE SIMIAN HERPESVIRUSES. R. Eberle et al.; Infect Agents Dis (Jun 1995; 4(2)). Pp. 55-70.

A CONTROLLED SEROPREVALENCE SURVEY OF PRIMATE HANDLERS FOR EVIDENCE OF ASYMPTOMATIC HERPES B VIRUS INFECTION. A.G. Freifeld et al.; J Infect Dis (Apr 1995; 171(4)). Pp. 1031-34.

GUIDELINES FOR THE PREVENTION AND TREATMENT OF B-VIRUS INFECTIONS IN EXPOSED PERSONS. THE B VIRUS WORKING GROUP. G.P. Holmes et al.; Clin Infect Dis (Feb 1995; 20(2)). Pp. 421-39.

THREAT TO HUMANS FROM VIRUS INFECTIONS OF NON-HUMAN PRIMATES. D.W. Brown; Rev Med Virol (Dec 1997; 7(4)). Pp. 239-246.

B-VIRUS FROM PET MACAQUE MONKEYS: AN EMERGING THREAT IN THE UNITED STATES? S.R. Ostrowski et al.; Emerg Infec Dis (Jan-Mar 1998; 4(1)). Pp. 117-21.

FATAL CERCOPITHECINE HERPESVIRUS 1 (B VIRUS) INFECTION FOLLOWING A MUCOCUTANEOUS EXPOSURE AND INTERIM RECOMMENDATIONS FOR WORKER PROTECTION. MMWR Morb Mortal Wkly Rep (Dec 18 1998; 47(49)). Pp. 1073-76, 1083.

HERPES B VIRUS INFECTION. A. Jainkittivong et al.; Oral Surg Oral Med Oral Pathol Oral Radiol Endod (Apr 1998; 85(4)). Pp. 399-403.

Resources

Transverse Myelitis Association
1787 Sutter Parkway
Powell, OH 43065-8806
USA
Tel: 6147661806
Email: ssiegel@myelitis.org
Internet: http://www.myelitis.org

Centers for Disease Control and Prevention
1600 Clifton Road NE
Atlanta, GA 30333
Tel: (404)639-3534
Tel: (800)311-3435
Email: http://www.cdc.gov/netinfo.htm
Internet: http://www.cdc.gov/

NIH/National Institute of Allergy and Infectious Diseases
6610 Rockledge Drive
MSC 6612
Bethesda, MD 20892-6612
Tel: (301)496-5717
Fax: (301)402-3573
TDD: (800)877-8339
Internet: http://www.niaid.nih.gov/

World Health Organization (WHO) Regional Office for the Americas (AMRO)
Pan American Health Organization (PAHO)
525 23rd Street NW
Washington, DC 20037
Tel: (202)974-3000
Fax: (202)974-3663
Email: postmaster@paho.org
Internet: http://www.who.ch/

Encephalitis Global
1638 Pierard Road
North Vancouver
British Columbia, Intl V7J 1Y2
Canada
Tel: 604-980-2236
Fax: 6049040809
Email: wendystation@shaw.ca
Internet: http://www.encephalitisglobal.com

Encephalitis Society
7B Saville Street
Malton, North Yorkshire, YO17 7LL
UK
Tel: 44 (0) 1652 625 583
Email: mail@encephalitis.info
Internet: http://www.encephalitis.info

The information provided in this report is not intended for diagnostic purposes. It is provided for informational purposes only. NORD recommends that affected individuals seek the advice or counsel of their own personal physicians.

It is possible that the title of this topic is not the name you selected. Please check the Synonyms listing to find the alternate name(s) and Disorder Subdivision(s) covered by this report

This disease entry is based upon medical information available through the date at the end of the topic. Since NORD's resources are limited, it is not possible to keep every entry in the Rare Disease Database completely current and accurate. Please check with the agencies listed in the Resources section for the most current information about this disorder.

For additional information and assistance about rare disorders, please contact the National Organization for Rare Disorders at P.O. Box 1968, Danbury, CT 06813-1968; phone (203) 744-0100; web site www.rarediseases.org or email orphan@rarediseases.org

Last Updated:  8/8/2007
Copyright  1987, 1989, 1999, 2007 National Organization for Rare Disorders, Inc.



This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.